486 related articles for article (PubMed ID: 18195491)
1. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M
Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
[TBL] [Abstract][Full Text] [Related]
3. Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M; Boczek-Leszczyk E
J Physiol Pharmacol; 2008 Sep; 59(3):553-62. PubMed ID: 18953097
[TBL] [Abstract][Full Text] [Related]
4. Role of tachykinin receptors and melatonin in oxitocin secretion from isolated rat hypothalmo-neurohypophysial system.
Juszczak M; Furykiewicz-Nykiś K; Stempniak B
J Physiol Pharmacol; 2004 Dec; 55(4):739-49. PubMed ID: 15613740
[TBL] [Abstract][Full Text] [Related]
5. Role for NK(1) and NK(2) receptors in the motor activity in mouse colon.
Mulè F; Amato A; Serio R
Eur J Pharmacol; 2007 Sep; 570(1-3):196-202. PubMed ID: 17597603
[TBL] [Abstract][Full Text] [Related]
6. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of gonadotrophin-releasing hormone (GnRH), its analogues and melatonin.
Boczek-Leszczyk E; Stempniak B; Juszczak M
J Physiol Pharmacol; 2010 Aug; 61(4):459-66. PubMed ID: 20814074
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin A and the neurohypophysial response to melatonin: in vitro studies.
Juszczak M
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 2):823-34. PubMed ID: 12510866
[TBL] [Abstract][Full Text] [Related]
9. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
10. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
[TBL] [Abstract][Full Text] [Related]
11. Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.
Ricciardolo FL; Trevisani M; Geppetti P; Nadel JA; Amadesi S; Bertrand C
Br J Pharmacol; 2000 Mar; 129(5):915-20. PubMed ID: 10696090
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological examination of the neurokinin-1 receptor mediating relaxation of human intralobar pulmonary artery.
Pedersen KE; Buckner CK; Meeker SN; Undem BJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):319-25. PubMed ID: 10604965
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
14. Tachykinin receptor subtypes in the isolated guinea pig heart and their role in mediating responses to neurokinin A.
Chang Y; Hoover DB; Hancock JC; Smith FM
J Pharmacol Exp Ther; 2000 Jul; 294(1):147-54. PubMed ID: 10871306
[TBL] [Abstract][Full Text] [Related]
15. Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers.
Brunelleschi S; Nicali R; Lavagno L; Viano I; Pozzi E; Gagliardi L; Ghio P; Albera C
Neuropeptides; 2000 Feb; 34(1):45-50. PubMed ID: 10688968
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
[TBL] [Abstract][Full Text] [Related]
18. Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK(2) receptors.
Kerr KP; Thai B; Coupar IM
Br J Pharmacol; 2000 Dec; 131(7):1461-7. PubMed ID: 11090121
[TBL] [Abstract][Full Text] [Related]
19. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
Tauer U; Zhao Y; Hunt SP; Culman J
Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
